The average one-year price target for NeuroPace (NASDAQ:NPCE) has been revised to 9.86 / share. This is an increase of 5.45% from the prior estimate of 9.35 dated November 26, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 8.08 to a high of 12.60 / share. The average price target represents an increase of 10.91% from the latest reported closing price of 8.89 / share.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in NeuroPace. This is an increase of 2 owner(s) or 4.55% in the last quarter. Average portfolio weight of all funds dedicated to NPCE is 1.80%, an increase of 88.87%. Total shares owned by institutions increased in the last three months by 2.91% to 18,137K shares.
What are Other Shareholders Doing?
Kck holds 5,621K shares representing 21.39% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 4,012K shares representing 15.27% ownership of the company. No change in the last quarter.
Soleus Capital Management holds 2,466K shares representing 9.38% ownership of the company. In it's prior filing, the firm reported owning 2,466K shares, representing a decrease of 0.00%. The firm increased its portfolio allocation in NPCE by 79.85% over the last quarter.
Nantahala Capital Management holds 1,220K shares representing 4.64% ownership of the company. In it's prior filing, the firm reported owning 425K shares, representing an increase of 65.17%. The firm increased its portfolio allocation in NPCE by 449.65% over the last quarter.
FCPGX - Fidelity Small Cap Growth Fund holds 928K shares representing 3.53% ownership of the company. In it's prior filing, the firm reported owning 1,002K shares, representing a decrease of 8.03%. The firm decreased its portfolio allocation in NPCE by 29.31% over the last quarter.
NeuroPace Background Information
(This description is provided by the company.)
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
